Literature DB >> 2155727

Depressed degranulation response of synovial fluid polymorphonuclear leucocytes from patients with rheumatoid arthritis to IgG aggregates.

B Dularay1, P A Dieppe, C J Elson.   

Abstract

No difference was found between the degranulation responses to FMLP of synovial fluid (SF) polymorphonuclear leucocytes (PMNL), from patients with rheumatoid arthritis (RA), and either paired blood PMNL or blood PMNL from a healthy donor. In contrast, the response of SF PMNL to heat-aggregated IgG was often reduced compared with autologous blood PMNL. Similarly, SF from some (35%) RA patients stimulated degranulation of PMNL but the response of SF-derived PMNL to autologous stimulatory SF was reduced compared with the response of blood PMNL. The stimulatory activity of the SF was removed by sepharose-protein A. These results were taken to suggest that the activity is due to immunoglobulin aggregates and that SF PMNL (from some RA patients) are tachyphylactic to stimulation by immunoglobulin aggregates as measured by degranulation because they have been stimulated by immunoglobulin aggregates in vivo. In other studies the concentration of myeloperoxidase (MPO) was measured enzymically in RA SF and was found to be present in varying amounts. However, only a weak relationship was found between MPO levels and either PMNL numbers or levels of complement-bearing IgG aggregates in SF. It is considered that the relationship between MPO and immunoglobulin aggregates levels is obscured by the presence of a peroxidase inhibitor in the fluids and/or because only aggregates bound to tissue stimulate degranulation in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155727      PMCID: PMC1534756          DOI: 10.1111/j.1365-2249.1990.tb05178.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Lysosomal enzymes in inflammatory synovial effusions.

Authors:  N M Hadler; J K Spitznagel; R J Quinet
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

2.  The immunologic release of constituents from neutrophil leukocytes. II. Mechanisms of release during phagocytosis, and adherence to nonphagocytosable surfaces.

Authors:  P M Henson
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

3.  Release of lysosomal enzymes from human polymorphonuclear leukocytes by soluble intermediate immune complexes.

Authors:  A D Morrison; W Pruzanski; N S Ranadive
Journal:  Scand J Rheumatol       Date:  1978       Impact factor: 3.641

4.  Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis.

Authors:  I M Goldstein; D Roos; H B Kaplan; G Weissmann
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

5.  Protein A reactivity of various mammalian immunoglobulins.

Authors:  J Goudswaard; J A van der Donk; A Noordzij; R H van Dam; J P Vaerman
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

6.  Degradation of cartilage proteoglycan by human leukocyte granule neutral proteases--a model of joint injury. II. Degradation of isolated bovine nasal cartilage proteoglycan.

Authors:  H Keiser; R A Greenwald; G Feinstein; A Janoff
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

7.  Stimulation of human neutrophils by soluble and insoluble immunoglobulin aggregates. Secretion of granule constituents and increased oxidation of glucose.

Authors:  P M Henson; Z G Oades
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

8.  Connective tissue-degrading enzymes of human leukocytes.

Authors:  A L Oronsky; R J Perper
Journal:  Ann N Y Acad Sci       Date:  1975-06-13       Impact factor: 5.691

9.  Enhanced oxidative response of polymorphonuclear leukocytes from synovial fluids of patients with rheumatoid arthritis.

Authors:  B Dularay; C J Elson; P A Dieppe
Journal:  Autoimmunity       Date:  1988       Impact factor: 2.815

10.  Selective neutrophil desensitization to chemotactic factors.

Authors:  J T O'Flaherty; D L Kreutzer; H J Showell; G Vitkauskas; E L Becker; P A Ward
Journal:  J Cell Biol       Date:  1979-03       Impact factor: 10.539

View more
  7 in total

Review 1.  Kallikreins and kinins: mediators in inflammatory joint disease?

Authors:  K Worthy; C D Figueroa; P A Dieppe; K D Bhoola
Journal:  Int J Exp Pathol       Date:  1990-08       Impact factor: 1.925

2.  Inhibition of myeloperoxidase by synovial fluid and serum.

Authors:  B Dularay; C M Yea; C J Elson
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

3.  Oxidative response of polymorphonuclear leucocytes to synovial fluids from patients with rheumatoid arthritis.

Authors:  B Dularay; J S Badesha; P A Dieppe; C J Elson
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

4.  Activation of neutrophil reactive-oxidant production by synovial fluid from patients with inflammatory joint disease. Soluble and insoluble immunoglobulin aggregates activate different pathways in primed and unprimed cells.

Authors:  J Robinson; F Watson; R C Bucknall; S W Edwards
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

5.  Identification of a myeloperoxidase inhibitor from normal human serum.

Authors:  C M Yea; B Dularay; C J Elson
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

6.  Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis.

Authors:  M M Rahman; K D Bhoola; C J Elson; M Lemon; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1995-05       Impact factor: 19.103

7.  Milano summer particulate matter (PM10) triggers lung inflammation and extra pulmonary adverse events in mice.

Authors:  Francesca Farina; Giulio Sancini; Cristina Battaglia; Valentina Tinaglia; Paride Mantecca; Marina Camatini; Paola Palestini
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.